Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Transkaryotic, Sanofi-Aventis SA deal

SNY granted TKTX rights to clinical trial results from a Phase III trial of Dynepo

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE